Table 1 Demographical and clinical characteristic of subjects in this study.

From: Anti-protein arginine methyltransferase 5 (PRMT5) antibodies is associated with interstitial lung disease in rheumatoid arthritis

 

Control (n = 31)

SSc (n = 33)

RA (n = 87)

Male/female

11/20

13/20

27/60

Age in years (mean ± SD)

60.3 ± 8.9

54.7 ± 13.5

61.6 ± 10.8

Disease duration in years,

median (Q1-Q3)

–

2.0 (1.0-8.5)

8.0 (3.0–20.0)

Autoantibodies

   

ANA

–

90.9% (30/33)

31.0% (26/84)

ANA titer*, median (range)

–

1:640 (1:160–1:10000)

1:90 (1:80–1:1600)

RF

–

–

81.9% (68/83)

ACPA

–

–

86.3% (69/80)

ATA

–

51.5% (17/33)

–

ACA

–

9.1% (3/33)

–

Anti-Ro60

–

–

9.2% (8/87)

Anti-Ro52

–

–

10.4%(9/85)

RA-ILD grade

   

0

–

–

29.9% (26/87)

1

–

–

25.3% (22/87)

2

–

–

26.4% (23/87)

3

–

–

18.4% (16/87)

SSc subtype

   

lcSSc

–

66.7% (22/33)

–

dcSSc

–

33.3% (11/33)

–

  1. *ANA was determined using an indirect immunofluorescence assay with HEp-2 cells, and a titer over 1:80 was considered positive. Descriptive statistics of ANA titer was performed with 22 SSc patients and 24 RA patients with recorded ANA titer values. RA, rheumatoid arthritis; SSc, systemic sclerosis; ILD, interstitial lung disease; ANA, antinuclear antibodies; RF, rheumatoid factor; ACPA, anti-citrullinated protein antibodies; ATA, anti-topoisomerase antibodies. ACA, anti- centromere protein B antibodies.
Back to article page